Ernexa Therapeutics Inc.
ERNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000748592
No open-market purchases or sales by Ernexa Therapeutics Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $236.2K in total; no superinvestor holds it.
Other share classesERNAW
13F holders, Q2 2026
Institutional positions in Ernexa Therapeutics Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −10 vs. Q1 2026
- Shares held
- 35.5K
- −3.54M (−99.0%) vs. Q1 2026
- Total value
- $236.2K
- −$475.2K (−66.8%) vs. Q1 2026
- New holders
- 2
- 0 more added
- Sold out
- 12
- 8 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ERNA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $236.2K |
| Q1 2026 | 20 | $711.4K |
| Q4 2025 | 14 | $1.15M |
| Q3 2025 | 14 | $566.0K |
| Q2 2025 | 12 | $91.7K |
| Q1 2025 | 27 | $264.2K |
| Q4 2024 | 24 | $292.4K |
| Q3 2024 | 20 | $746.9K |
| Q2 2024 | 20 | $712.4K |
| Q1 2024 | 23 | $982.3K |
| Q4 2023 | 20 | $637.0K |
| Q3 2023 | 22 | $728.4K |
| Q2 2023 | 20 | $750.2K |
| Q1 2023 | 21 | $1.14M |
| Q4 2022 | 20 | $1.19M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Ernexa Therapeutics Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 15,104 | $100.4K | 0.00% | −17,972−54.3% | Reduced |
| Vanguard Fiduciary Trust Co | 8,336 | $55.4K | 0.00% | −17,111−67.2% | Reduced |
| Dauntless Investment Group, LLC | 6,000 | $39.9K | 0.07% | −606,443−99.0% | Reduced |
| Vanguard Capital Management LLC | 5,684 | $37.8K | 0.00% | −20,820−78.6% | Reduced |
| Tradewinds Capital Management, LLC | 361 | $2.40K | 0.00% | +361 | New |
| BlackRock, Inc. | 33 | $219 | 0.00% | −787−96.0% | Reduced |
| Assetmark, Inc | 5 | $33 | 0.00% | −128−96.2% | Reduced |
| BNP Paribas Arbitrage, SA | 1 | $7 | 0.00% | −9−90.0% | Reduced |
| SBI Securities Co., Ltd. | 1 | $7 | 0.00% | −5−83.3% | Reduced |
| Steward Partners Investment Advisory, LLC | 0 | $1 | 0.00% | 0 | New |
| Activest Wealth Management | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Bleichroeder LP | 0 | $0 | 0.00% | −2,000,000−100.0% | Sold out |
| CI Private Wealth, LLC | 0 | $0 | 0.00% | −438,093−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −244,446−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −54,338−100.0% | Sold out |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −41,167−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −21,233−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −16,631−100.0% | Sold out |
| Sippican Capital Advisors | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Montag A & Associates Inc | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −1−100.0% | Sold out |